Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants

Core Viewpoint - Jaguar Health has strengthened its balance sheet through restructuring, reducing royalty obligations and debt, and extinguishing warrants, which is a key priority for the company [1] Financial Restructuring - The company has reduced its royalty obligations and debt by approximately 10%, equating to a reduction of about $3 million [1] - The maturity date for a secured revolving line of credit of approximately $7 million has been extended by three years, ensuring no maturity dates before July 2026 for any debt held by affiliates of Chicago Venture Partners L.P. [1] Operational Focus - Jaguar Health continues to focus on its global development program for crofelemer, aimed at treating rare-disease intestinal failure indications [1] - The intestinal failure program is expected to provide clinical proof-of-concept milestones and is involved in business development discussions to potentially secure non-dilutive funding from licensee partners [1] Product Information - Crofelemer is a novel, oral plant-based prescription medicine derived from the red bark sap of the Croton lechleri tree, known for its sustainable harvesting practices [1] - The company, along with its subsidiaries Napo Pharmaceuticals and Napo Therapeutics, is dedicated to developing and commercializing crofelemer for gastrointestinal disorders [1]